Laurent Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Laurent Pharma develops a Phase 2 small molecule oral drug (LAU-7b) with a dual MOA, targeting two rare diseases (Stargardt and IPF). LAU-7b capitalizes on years of clinical development confirming its good safety profile and evidence of efficacy in both macular degeneration and lung fibrosis.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}